Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lv1a
- Development stage
- Unknown
- Lead developer
- The University of Queensland
- Modality
- Peptides
01
Overview
Lv1a: sourced facts only. name: "Pharmacological profiling of Lv1a revealed a preference for inhibiting human NaV1.6 subtype, whose dysfunction can lead to neurotransmission block, muscle paralysis and potential death." [PMID:41319925]; target: "Pharmacological profiling of Lv1a revealed a preference for inhibiting human NaV1.6 subtype, whose dysfunction can lead to neurotransmission block, muscle paralysis and potential death." [PMID:41319925]; developer: "Institute for Molecular Bioscience, The University of Queensland, St Lucia, Brisbane 4072 Queensland, Australia." [PMID:41319925]; modality: "including Lv1a, a 35 residues peptide with a typical inhibitory cysteine knot motif" [PMID:41319925]
02
Targets
SCN8A (NaV1.6)
Beyond the preview
Go deeper on Lv1a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lv1a.